Raymond James & Associates’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $83.6K | Sell |
50,657
-6,220
| -11% | -$10.3K | ﹤0.01% | 3758 |
|
|
2024
Q2 | $126K | Hold |
56,877
| – | – | ﹤0.01% | 3662 |
|
|
2024
Q1 | $152K | Buy |
56,877
+17,527
| +45% | +$47K | ﹤0.01% | 3638 |
|
|
2023
Q4 | $118K | Buy |
39,350
+17,636
| +81% | +$52.7K | ﹤0.01% | 3592 |
|
|
2023
Q3 | $21.3K | Buy |
21,714
+4,578
| +27% | +$4.49K | ﹤0.01% | 3694 |
|
|
2023
Q2 | $23.8K | Buy |
17,136
+2,798
| +20% | +$3.89K | ﹤0.01% | 3710 |
|
|
2023
Q1 | $22.8K | Sell |
14,338
-23,590
| -62% | -$37.5K | ﹤0.01% | 3737 |
|
|
2022
Q4 | $236K | Buy |
+37,928
| New | +$236K | ﹤0.01% | 3330 |
|
|
2022
Q3 | – | Sell |
-10,840
| Closed | -$69K | – | 3841 |
|
|
2022
Q2 | $69K | Buy |
+10,840
| New | +$69K | ﹤0.01% | 3699 |
|
|
2021
Q2 | – | Sell |
-22,721
| Closed | -$637K | – | 3925 |
|
|
2021
Q1 | $637K | Buy |
22,721
+11,161
| +97% | +$313K | ﹤0.01% | 2822 |
|
|
2020
Q4 | $301K | Buy |
11,560
+2,667
| +30% | +$69.4K | ﹤0.01% | 3094 |
|
|
2020
Q3 | $331K | Buy |
8,893
+3,928
| +79% | +$146K | ﹤0.01% | 2875 |
|
|
2020
Q2 | $255K | Buy |
+4,965
| New | +$255K | ﹤0.01% | 2991 |
|
|
2020
Q1 | – | Sell |
-3,975
| Closed | -$237K | – | 3448 |
|
|
2019
Q4 | $237K | Buy |
+3,975
| New | +$237K | ﹤0.01% | 3214 |
|
|
2019
Q3 | – | Sell |
-5,060
| Closed | -$235K | – | 3509 |
|
|
2019
Q2 | $235K | Buy |
+5,060
| New | +$235K | ﹤0.01% | 3126 |
|
|
2018
Q4 | – | Sell |
-6,699
| Closed | -$297K | – | 3474 |
|
|
2018
Q3 | $297K | Buy |
+6,699
| New | +$297K | ﹤0.01% | 3022 |
|
|
2017
Q3 | – | Sell |
-5,200
| Closed | -$241K | – | 3274 |
|
|
2017
Q2 | $241K | Buy |
+5,200
| New | +$241K | ﹤0.01% | 2851 |
|